Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4161/cbt.10.11.13786 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
DBC2/RhoBTB2 functions as a tumor suppressor protein via Musashi-2 ubiquitination in breast cancer.
Oncogene
May 2017
KU Center for Integrated Science and Technology, Konkuk University, Seoul, South Korea.
The gene encoding 'deleted in breast cancer 2' (DBC2), also referred to as RHOBTB2 (Rho-related BTB domain-containing protein 2), is classified as a tumor suppressor gene. DBC2 is a substrate-specific adaptor protein for a novel class of Cullin-3 (CUL3)-based E3 ubiquitin ligases; however, it is unclear if the substrate adaptor function of DBC2 is required for its tumor suppressor activity. Furthermore, the key substrates of DBC2-mediated ubiquitination have yet to be identified.
View Article and Find Full Text PDFRhoBTB2 (DBC2) functions as a multifunctional tumor suppressor in thyroid cancer cells via mitochondrial apoptotic pathway.
Int J Clin Exp Med
July 2015
Department of Vascular and Thyroid Surgery, The First Affiliated Hospital of China Medical University Nanjing North Street 155, Heping District, Shenyang City 110001, Liaoning Province, P. R. China.
Thyroid cancer is the most common endocrine malignancy worldwide. Tumor suppressor gene RhoBTB2 (also known as Deleted in Breast Cancer 2, DBC2) was observed in various carcinomas, however, no reports showed the effects of RhoBTB2 on thyroid cancer. In our study, we found that RhoBTB2 decreases proliferation, increases apoptosis, inhibits mobility, and induces mitochondria damage in SW579 cells through increased Bax and decreased Bcl-2 and Bcl-xL protein expression.
View Article and Find Full Text PDFHsp90-dependent assembly of the DBC2/RhoBTB2-Cullin3 E3-ligase complex.
PLoS One
December 2014
Department of Biochemistry and Molecular Biology, Oklahoma State University, Stillwater, Oklahoma, United States of America.
The expression of the wild-type tumor-suppressor gene DBC2 (Deleted-in-Breast Cancer 2, a.k.a RhoBTB2) is suppressed in many cancers, in addition to breast cancer.
View Article and Find Full Text PDFThe mutation of DBC2 in breast cancer patients from the Han ethnic group in Eastern China.
Hematol Oncol Stem Cell Ther
June 2014
Department of Oncology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China. Electronic address:
Objective: To investigate DBC2 mutations in breast cancer patients and evaluate the relationship between gene mutations and breast cancer susceptibility in an Eastern China population.
Methods: Mutation analyses of 285bp promoter sequence, coding exon 7 and its exon/intron boundaries of DBC2 were performed in 32 breast cancer specimens by polymerase chain reaction and direct sequencing. Eighteen benign breast tumor specimens were also analyzed as control.
Decreased expression of the DBC2 gene and its clinicopathological significance in breast cancer: correlation with aberrant DNA methylation.
Biotechnol Lett
August 2013
Department of Biochemistry and Molecular Biology, Medical College, Qingdao University, Qingdao, 266021, Shandong, China.
Loss of DBC2 (deleted in breast cancer 2) gene expression is frequent in breast cancer tissues. This can be explained by homozygous deletions or other mutations in a minority of cases but alternative mechanisms need to be investigated. Here, DBC2 expression was significantly suppressed compared with normal breast tissues in breast cancer tissues when analyzed by RT-PCR.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!